Nuntius Therapeutics
Cell-specific genetic medicines
Y CombinatorWinter 2021ActiveHealthcareTherapeuticsGene TherapyNanomedicine
What they do
Problem
Genetic medicines often cannot precisely target specific cell types, limiting effectiveness and increasing side effects.
Solution
Nuntius Therapeutics develops cell-specific genetic medicines designed to deliver therapeutic genetic payloads to targeted cell populations.
Who it's for
Biopharmaceutical companies and clinical researchers developing targeted gene and RNA therapies.
Founders
Benita Nagel
Founder
Albert Kwok
Founder
Company timeline
- Founded2021
- YC batchWinter 2021
- StatusActive
- Team size2 people
- LocationLondon, England, United Kingdom
Similar startups
Engage Bio
Potent, durable, and redosable non-viral genetic medicines
Amber
RNA writing (trans-splicing) for correction of genetic diseases
BreezeBio
BreezeBio is a genetic medicines company pioneering precision-deliver…
WhiteLab Genomics
Unleashing the potential of DNA and RNA based therapies using AI
Serna Bio
Genetic Medicine with Small Molecules
Camp4
Biology is elegant, but it’s rarely simple. Following the completion…